Search
Close this search box.
    • Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Search
Close this search box.

Scientific Posters

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Efficient Scale Up of Therapeutic Antibody Manufacturing Processes

Syngene’s ‘first-time-right’ Technology Transfer approach to achieve timely clinical and commercial milestones.

Read
Mechanistic insights into drug-drug interactions from large-scale toxicogenomics data

How to manage the risk of drug-drug interactions in drug development and during poly therapy especially with elderly patients.

Read
Profiling CEACAM7 as a potential target for pancreatic cancer

Demonstrating the therapeutic edge of targeting CEACAM7 in pancreatic cancer using an integrative approach between biology and bioinformatics.

Read

Sign-up for our newsletter

© 2024. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2024. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

Close

To view or email, Please share your details view

To download, Please share your details